EMBioSys, Inc.
About EMBioSys, Inc.
EMBioSys, Inc. was founded in 2022 with a mission to develop innovative bioelectric solutions that transform the future of cancer care. The company is entering clinical trials with Efiniaβ’, a revolutionary platform for the treatment of cancer starting with breast cancer, including triple negative breast cancer. It operates in Healthcare & Life Sciences and Medical Equipment Manufacturing as a privately held B2B/B2C company headquartered in North Andover, Massachusetts.
Investors
Not disclosed in the source filing. Form D filings do not list investors β StreetZero surfaces them from news where available.
Key highlights
- EMBioSys is advancing Efiniaβ’ into clinical trials in 2026 for triple-negative breast cancer.
- The company has raised $600k in non-dilutive funding and is targeting a $2.5M Seed round.
- Partnered with NEMIC in 2024 for business advisory and fundraising support in Rhode Island ecosystem.
- Founded in 2022 in Massachusetts with focus on bioelectric cancer treatment platforms.
Ask StreetZero about EMBioSys, Inc.
Put our AI to work on this deal.
Similar companies
Other Crowdfunding deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account